TEL/AML1 real-time quantitative reverse transcriptase PCR can complement minimal residual disease assessment in childhood ALL [14]

Leukemia

Volumn 19, Issue 7, 2005, Pages 1296-1297

  Fronkova, E ^a   Madzo, J ^a   Zuna, J ^a   Reznickova, L ^a   Muzikova, K ^a   Hrusak, O ^a   Stary, J ^a   Trka, Jan ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR RUNX1; LYMPHOCYTE ANTIGEN RECEPTOR; ONCOPROTEIN; TEL AML1 FUSION PROTEIN; TEL-AML1 FUSION PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; FOLLOW UP; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; INTERMETHOD COMPARISON; LETTER; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ACUTE LYMPHOCYTIC LEUKEMIA; COMPARATIVE STUDY; GENETICS; METHODOLOGY; PROSPECTIVE STUDY;

CHILD; CORE BINDING FACTOR ALPHA 2 SUBUNIT; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 21744447214     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403759     Document Type: Letter

References (8)

1. Madzo J, Zuna J, Muzikova K, Kalinova M, Krejci O, Hrusak O et al. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer 2003; 97: 105-113.
2. Drunat S, Olivi M, Brunie G, Grandchamp B, Vilmer E, Bieche I et al. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia. Br J Haematol 2001; 114: 281-289.
3. de Haas V, Breunis WB, Dee R, Verhagen OJ, Kroes W, van Wering ER et al. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia. Br J Haematol 2002; 116: 87-93.
4. Taube T, Eckert C, Korner G, Henze G, Seeger K. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods. Leuk Res 2004; 28: 699-706.
5. Van Der Velden VH, Hochhaus A, Cazzaniga G, Szczepanski T, Gabert J, Van Dongen JJ. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003; 17: 1013-1034.
6. Verhagen OJ, Willemse MJ, Breunis WB, Wijkhuijs AJ, Jacobs DC, Joosten SA et al. Application of germline IGH probes in realtime quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia. Leukemia 2000; 14: 1426-1435.
7. Szczepanski T, Pongers Willemse MJ, Langerak AW, Harts WA, Wijkhuijs AJ, van Wering ER et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999; 93: 4079-4085.
8. Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 110-118.